Fundamental Analysis of ETERNA THERAPEUTICS INC(NASDAQ:ERNA) stock

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to ERNA. ERNA was compared to 561 industry peers in the Biotechnology industry. Both the profitability and financial health of ERNA have multiple concerns. ERNA has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

ERNA had negative earnings in the past year.

ERNA had a negative operating cash flow in the past year.

In the past 5 years ERNA always reported negative net income.

ERNA had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

With a Return On Assets value of -582.39%, ERNA is not doing good in the industry: 98.38% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-582.39%
ROE	N/A
ROIC	N/A

ROA(3y)-181.08%

ROA(5y)-135.19%

ROE(3y)-551.61%

ROE(5y)-443.3%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of ERNA (72.91%) is better than 83.96% of its industry peers.

ERNA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	72.91%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ERNA does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for ERNA has been increased compared to 1 year ago.

ERNA has more shares outstanding than it did 5 years ago.

The debt/assets ratio for ERNA is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -50.18, we must say that ERNA is in the distress zone and has some risk of bankruptcy.

ERNA has a worse Altman-Z score (-50.18) than 94.59% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-50.18

ROIC/WACCN/A

WACC9.27%

2.3 Liquidity

ERNA has a Current Ratio of 0.48. This is a bad value and indicates that ERNA is not financially healthy enough and could expect problems in meeting its short term obligations.

The Current ratio of ERNA (0.48) is worse than 93.69% of its industry peers.

A Quick Ratio of 0.48 indicates that ERNA may have some problems paying its short term obligations.

The Quick ratio of ERNA (0.48) is worse than 93.33% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.48
Quick Ratio	0.48

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ERNA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -98.75%.

Looking at the last year, ERNA shows a very strong growth in Revenue. The Revenue has grown by 1096.00%.

Measured over the past years, ERNA shows a very negative growth in Revenue. The Revenue has been decreasing by -68.89% on average per year.

EPS 1Y (TTM)-98.75%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-377.43%

Revenue 1Y (TTM)1096%

Revenue growth 3Y-77.28%

Revenue growth 5Y-68.89%

Sales Q2Q%874%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ERNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ERNA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ETERNA THERAPEUTICS INC

NASDAQ:ERNA (1/6/2025, 8:00:01 PM)

After market: 0.349 +0.02 (+5.82%)

0.3298

-0.01 (-4.13%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-11 2024-11-11/amc

Earnings (Next)03-12 2025-03-12

Inst Owners7.21%

Inst Owner Change0%

Ins Owners8.45%

Ins Owner Change0%

Market Cap16.94M

Analysts43.33

Price TargetN/A

Short Float %1.83%

Short Ratio0.64

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)-60.39%

DP-0.03%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	28.33
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-8.31

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-0.34

FCFYN/A

OCF(TTM)-0.33

OCFYN/A

SpS0.01

BVpS-0.88

TBVpS-0.92

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-582.39%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	72.91%
FCFM	N/A

ROA(3y)-181.08%

ROA(5y)-135.19%

ROE(3y)-551.61%

ROE(5y)-443.3%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0.08

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	269.44%
Cap/Sales	64.88%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.48
Quick Ratio	0.48
Altman-Z	-50.18

F-Score3

WACC9.27%

ROIC/WACCN/A

Cap/Depr(3y)111.71%

Cap/Depr(5y)77.7%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-98.75%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-377.43%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)1096%

Revenue growth 3Y-77.28%

Revenue growth 5Y-68.89%

Sales Q2Q%874%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-3.35%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y23.93%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y24.23%

OCF growth 3YN/A

OCF growth 5YN/A

ETERNA THERAPEUTICS INC (ERNA)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens